RU2017116973A - Способы применения и композиции нейрегулинов для предотвращения, лечения или замедления сердечной недостаточности с сохраненной фракцией выброса - Google Patents
Способы применения и композиции нейрегулинов для предотвращения, лечения или замедления сердечной недостаточности с сохраненной фракцией выброса Download PDFInfo
- Publication number
- RU2017116973A RU2017116973A RU2017116973A RU2017116973A RU2017116973A RU 2017116973 A RU2017116973 A RU 2017116973A RU 2017116973 A RU2017116973 A RU 2017116973A RU 2017116973 A RU2017116973 A RU 2017116973A RU 2017116973 A RU2017116973 A RU 2017116973A
- Authority
- RU
- Russia
- Prior art keywords
- heart failure
- pharmaceutical preparation
- mammal
- neuregulin
- composition
- Prior art date
Links
- 206010019280 Heart failures Diseases 0.000 title claims 6
- 102000014413 Neuregulin Human genes 0.000 title claims 6
- 108050003475 Neuregulin Proteins 0.000 title claims 6
- 239000000203 mixture Substances 0.000 title claims 2
- 230000002265 prevention Effects 0.000 title 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 7
- 241000124008 Mammalia Species 0.000 claims 6
- 102100040896 Growth/differentiation factor 15 Human genes 0.000 claims 2
- 101000893549 Homo sapiens Growth/differentiation factor 15 Proteins 0.000 claims 2
- 101000653754 Rattus norvegicus Sphingosine 1-phosphate receptor 5 Proteins 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1883—Neuregulins, e.g.. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Claims (10)
1. Применение нейрегулина при приготовлении лекарственного средства для предотвращения, лечения или замедления сердечной недостаточности с сохраненной фракцией выброса у млекопитающего.
2. Применение по п.1, где нейрегулин представляет собой NRG-1.
3. Применение по п.1, где нейрегулин содержит последовательность аминокислот SEQ ID NO: 1.
4. Применение по п.1, где млекопитающее представляет собой человека.
5. Фармацевтический препарат для предотвращения, лечения или замедления сердечной недостаточности с сохраненной фракцией выброса у млекопитающего, который содержит эффективное количество NRG.
6. Фармацевтический препарат по п.5, где нейрегулин представляет собой NRG-1.
7. Фармацевтический препарат по п.5, где нейрегулин содержит последовательность аминокислот SEQ ID NO: 1.
8. Фармацевтический препарат по п.5, где млекопитающее представляет собой человека.
9. Композиция для предотвращения, лечения или замедления сердечной недостаточности с сохраненной фракцией выброса у млекопитающего, которая содержит фармацевтический препарат по п.5 и другое лекарственное средство (лекарственные средства) для лечения сердечной недостаточности с сохраненной фракцией выброса.
10. Набор, используемый для предотвращения, лечения или замедления сердечной недостаточности с сохраненной фракцией выброса у млекопитающего, который содержит фармацевтический препарат по п.5 и инструкции относительно того как использовать этот фармацевтический препарат.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410550212.7A CN105561298A (zh) | 2014-10-17 | 2014-10-17 | 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物 |
| CN201410550212.7 | 2014-10-17 | ||
| PCT/CN2015/091459 WO2016058493A1 (zh) | 2014-10-17 | 2015-10-08 | 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2017116973A true RU2017116973A (ru) | 2018-11-19 |
| RU2017116973A3 RU2017116973A3 (ru) | 2019-05-06 |
Family
ID=55746124
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2017116973A RU2017116973A (ru) | 2014-10-17 | 2015-10-08 | Способы применения и композиции нейрегулинов для предотвращения, лечения или замедления сердечной недостаточности с сохраненной фракцией выброса |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US10561709B2 (ru) |
| EP (2) | EP3207940B1 (ru) |
| JP (4) | JP2017532343A (ru) |
| KR (2) | KR20230159650A (ru) |
| CN (3) | CN105561298A (ru) |
| AU (2) | AU2015333335B2 (ru) |
| CA (1) | CA2963322A1 (ru) |
| ES (1) | ES2924395T3 (ru) |
| RU (1) | RU2017116973A (ru) |
| WO (1) | WO2016058493A1 (ru) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0620819A2 (pt) | 2005-12-30 | 2011-11-22 | Zensun Shangai Science & Technology Ltd | uso de uma neuregulina (nrg) de liberação prolongada, nrg em uma liberação prolongada de uma dosagem baixa constante, e, composição de liberação prolongada para prevenir, tratar ou retardar uma doença ou distúrbio em um mamìfero |
| JP6096262B2 (ja) | 2009-08-25 | 2017-03-15 | ゼンサン （シャンハイ） サイエンス アンド テクノロジー，シーオー．，エルティーディー． | ニューレグリンに基づく心不全の治療方法 |
| CN102139095A (zh) | 2010-01-29 | 2011-08-03 | 上海泽生科技开发有限公司 | 神经调节蛋白用于预防、治疗或延迟心脏缺血再灌注损伤的方法和组合物 |
| WO2013053076A1 (en) | 2011-10-10 | 2013-04-18 | Zensun （Shanghai）Science & Technology Limited | Compositions and methods for treating heart failure |
| RU2650635C2 (ru) | 2012-10-08 | 2018-04-16 | Цзэньсунь (Шанхай) Сайенс Энд Текнолоджи, Ко., Лтд. | Композиции и способы лечения сердечной недостаточности у пациентов с диабетом |
| WO2014187342A1 (en) | 2013-05-22 | 2014-11-27 | Zensun (Shanghai) Science & Technology, Ltd. | Extended Release of Neuregulin for Treating Heart Failure |
| CN104758922A (zh) | 2014-01-03 | 2015-07-08 | 上海泽生科技开发有限公司 | 纽兰格林制剂的配方 |
| CN105497876B (zh) | 2014-09-24 | 2021-01-15 | 上海泽生科技开发股份有限公司 | 神经调节蛋白用于预防、治疗或延迟心脏室性心律失常的方法和组合物 |
| HUE066892T2 (hu) | 2018-04-11 | 2024-09-28 | Salubris Biotherapeutics Inc | Humán neuregulin-1 (NRG-1) rekombináns fúziós fehérje készítmény és alkalmazási eljárások |
| CN111407881A (zh) * | 2019-01-07 | 2020-07-14 | 上海泽生科技开发股份有限公司 | 神经调节蛋白用于预防、治疗或延迟心肌损伤的方法和组合物 |
| AR121035A1 (es) | 2019-04-01 | 2022-04-13 | Lilly Co Eli | Compuestos de neuregulina-4 y métodos de uso |
| CN113289002A (zh) * | 2020-02-24 | 2021-08-24 | 上海泽生科技开发股份有限公司 | 神经调节蛋白用于预防、治疗或延缓心力衰竭的方法和组合物 |
| CN116710139A (zh) * | 2020-11-12 | 2023-09-05 | 安进股份有限公司 | 通过施用奥美卡替莫卡必尔治疗心力衰竭的方法 |
| CN117797243A (zh) * | 2022-09-30 | 2024-04-02 | 上海泽生科技开发股份有限公司 | 神经调节蛋白及其应用 |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1989001489A1 (en) | 1987-08-10 | 1989-02-23 | Commonwealth Scientific And Industrial Research Or | Control of angiogenesis and compositions and methods therefor |
| US5530109A (en) | 1991-04-10 | 1996-06-25 | Ludwig Institute For Cancer Research | DNA encoding glial mitogenic factors |
| US7115554B1 (en) | 1993-05-06 | 2006-10-03 | Acorda Therapeutics, Inc. | Methods of increasing myotube formation or survival or muscle cell mitogenesis differentiation or survival using neuregulin GGF III |
| US5716930A (en) | 1991-04-10 | 1998-02-10 | Ludwig Institute For Cancer Research | Glial growth factors |
| US5834229A (en) | 1991-05-24 | 1998-11-10 | Genentech, Inc. | Nucleic acids vectors and host cells encoding and expressing heregulin 2-α |
| US6750196B1 (en) | 1995-03-27 | 2004-06-15 | Acorda Therapeutics | Methods of treating disorders of the eye |
| US5912326A (en) | 1995-09-08 | 1999-06-15 | President And Fellows Of Harvard College | Cerebellum-derived growth factors |
| ATE427353T1 (de) | 1997-02-10 | 2009-04-15 | Genentech Inc | Heregulin varianten |
| EP1028735A4 (en) | 1997-10-14 | 2003-08-06 | Cenes Pharmaceuticals Inc | THERAPEUTIC METHOD COMPRISING THE USE OF NEUREGULIN |
| US6054261A (en) | 1998-05-20 | 2000-04-25 | Q-Pharma, Inc. | Coenzyme Q10 compositions for organ protection during perfusion |
| AUPP785098A0 (en) | 1998-12-21 | 1999-01-21 | Victor Chang Cardiac Research Institute, The | Treatment of heart disease |
| US6635249B1 (en) | 1999-04-23 | 2003-10-21 | Cenes Pharmaceuticals, Inc. | Methods for treating congestive heart failure |
| CN1138785C (zh) | 1999-06-04 | 2004-02-18 | 周明东 | 生长因子神经调节蛋白及其类似物的新应用 |
| AUPQ105799A0 (en) | 1999-06-18 | 1999-07-08 | Victor Chang Cardiac Research Institute, The | Cell growth inhibition |
| MXPA02008239A (es) | 2000-02-28 | 2004-08-12 | Decode Genetics Ehf | Gen humano de la esquizofrenia. |
| JP5324732B2 (ja) | 2000-05-23 | 2013-10-23 | スネス ファーマシューティカルズ インコーポレイテッド | Ｎｒｇ−２核酸分子、ポリペプチド、ならびに診断および治療法 |
| AU2001290864A1 (en) | 2000-09-12 | 2002-04-02 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Optimized cardiac contraction through differential phosphorylation of myosin |
| US6482624B2 (en) | 2000-11-14 | 2002-11-19 | Pe Corporation (Ny) | Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| RU2180843C1 (ru) | 2001-02-19 | 2002-03-27 | Новокузнецкий государственный институт усовершенствования врачей | Способ профилактики повторного инфаркта миокарда |
| CN1498656A (zh) | 2002-11-08 | 2004-05-26 | 上海泽生科技开发有限公司 | 神经调节蛋白用于心肌梗死治疗的方法和组合物 |
| WO2003099320A1 (en) | 2002-05-24 | 2003-12-04 | Zensun (Shanghai) Sci-Tech.Ltd | Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy |
| CA2506630A1 (en) | 2002-11-27 | 2004-06-17 | Artesian Therapeutics, Inc. | Heart failure gene determination and therapeutic screening |
| AU2004249114A1 (en) | 2003-05-21 | 2004-12-29 | Board Of Regents, The University Of Texas System | Inhibition of protein kinase C-mu (PKD) as a treatment for cardiac hypertrophy and heart failure |
| CN1715926B (zh) | 2004-07-02 | 2011-08-17 | 上海泽生科技开发有限公司 | 神经调节蛋白突变体的应用 |
| US20080213395A1 (en) | 2004-10-14 | 2008-09-04 | Adventures Plus Pty Ltd | Method for the Treatment of Gastrointestinal and Other Disorders with an Admixture of Vitamins |
| US20060160062A1 (en) | 2005-01-14 | 2006-07-20 | Young Lindon H | Perfusion and/or preservation solution for organs |
| US20070141548A1 (en) | 2005-03-11 | 2007-06-21 | Jorg Kohl | Organ transplant solutions and method for transplanting organs |
| CN100361709C (zh) | 2005-08-30 | 2008-01-16 | 山东省生物药物研究院 | 一种对生命活性物质有保护作用的糖类组合 |
| CN1768859A (zh) | 2005-10-24 | 2006-05-10 | 天津大学 | 基于醛基的微粒表面多重生物功能因子组装方法 |
| US20070213264A1 (en) | 2005-12-02 | 2007-09-13 | Mingdong Zhou | Neuregulin variants and methods of screening and using thereof |
| CN101394861A (zh) * | 2005-12-30 | 2009-03-25 | 上海泽生科技开发有限公司 | 纽兰格林持续给药能改善心脏功能 |
| BRPI0620819A2 (pt) | 2005-12-30 | 2011-11-22 | Zensun Shangai Science & Technology Ltd | uso de uma neuregulina (nrg) de liberação prolongada, nrg em uma liberação prolongada de uma dosagem baixa constante, e, composição de liberação prolongada para prevenir, tratar ou retardar uma doença ou distúrbio em um mamìfero |
| US9580515B2 (en) | 2006-08-21 | 2017-02-28 | Zensun (Shanghai) Science & Technology, Co., Ltd. | Neukinase, a downstream protein of neuregulin |
| CN106908603B (zh) | 2007-01-25 | 2019-04-02 | 霍夫曼-拉罗奇有限公司 | Igfbp-7在心力衰竭评估中的用途 |
| CN101310766B (zh) | 2007-05-25 | 2014-04-16 | 上海泽生科技开发有限公司 | 神经调节蛋白的新用途 |
| CN101310779A (zh) | 2007-05-25 | 2008-11-26 | 上海泽生科技开发有限公司 | 包含神经调节蛋白的装置及药物制剂 |
| US20090156488A1 (en) | 2007-09-12 | 2009-06-18 | Zensun (Shanghai) Science & Technology Limited | Use of neuregulin for organ preservation |
| CA2731113A1 (en) * | 2008-07-17 | 2010-03-18 | Acorda Therapeutics, Inc. | Therapeutic dosing of a neuregulin or a subsequence thereof for treatment or prophylaxis of heart failure |
| JP2012509908A (ja) | 2008-11-28 | 2012-04-26 | ゼンサン （シャンハイ） サイエンス アンド テクノロジー リミテッド | ニューレグリン及び心臓幹細胞 |
| WO2010060265A1 (en) | 2008-11-28 | 2010-06-03 | Zensun (Shanghai) Science & Technology Limited | Neuregulin peptides and their use |
| EP2440236B1 (en) * | 2009-06-09 | 2016-05-04 | Zensun (Shanghai) Science and Technology Limited | Neuregulin based methods for treating heart failure |
| JP2013503110A (ja) * | 2009-06-09 | 2013-01-31 | ゼンサン （シャンハイ） サイエンス アンド テクノロジー リミテッド | ニューレグリンに基づく心不全の治療方法 |
| JP6096262B2 (ja) | 2009-08-25 | 2017-03-15 | ゼンサン （シャンハイ） サイエンス アンド テクノロジー，シーオー．，エルティーディー． | ニューレグリンに基づく心不全の治療方法 |
| CN102139095A (zh) | 2010-01-29 | 2011-08-03 | 上海泽生科技开发有限公司 | 神经调节蛋白用于预防、治疗或延迟心脏缺血再灌注损伤的方法和组合物 |
| SI2544537T1 (sl) | 2010-03-10 | 2017-12-29 | Cempra Pharmaceuticals, Inc. | Formulacije makrolidnih antibiotikov za parenteralni vnos |
| EP2555788B1 (en) | 2010-03-24 | 2017-10-11 | Massachusetts Institute of Technology | NEUREGULIN DIMER FOR AN ErbB/HER RECEPTOR FOR USE IN REDUCING CARDIOTOXICITY. |
| CA2806208C (en) | 2010-07-22 | 2018-02-13 | Zishan Haroon | Methods of treating or ameliorating diseases and enhancing performance comprising the use of a magnetic dipole stabilized solution |
| WO2013053076A1 (en) | 2011-10-10 | 2013-04-18 | Zensun （Shanghai）Science & Technology Limited | Compositions and methods for treating heart failure |
| HK1206779A1 (en) | 2012-04-02 | 2016-01-15 | Modernatx, Inc. | Modified polynucleotides for the production of nuclear proteins |
| RU2650635C2 (ru) | 2012-10-08 | 2018-04-16 | Цзэньсунь (Шанхай) Сайенс Энд Текнолоджи, Ко., Лтд. | Композиции и способы лечения сердечной недостаточности у пациентов с диабетом |
| US20160129084A1 (en) * | 2013-03-06 | 2016-05-12 | Acorda Therapeutics, Inc. | Therapeutic Dosing of a Neuregulin or a Fragment Thereof for Treatment or Prophylaxis of Heart Failure |
| WO2014187342A1 (en) | 2013-05-22 | 2014-11-27 | Zensun (Shanghai) Science & Technology, Ltd. | Extended Release of Neuregulin for Treating Heart Failure |
| CN104758300A (zh) | 2014-01-02 | 2015-07-08 | 上海泽生科技开发有限公司 | 维生素d及其组合物的抗菌用途 |
| CN104758922A (zh) | 2014-01-03 | 2015-07-08 | 上海泽生科技开发有限公司 | 纽兰格林制剂的配方 |
| CN105497876B (zh) | 2014-09-24 | 2021-01-15 | 上海泽生科技开发股份有限公司 | 神经调节蛋白用于预防、治疗或延迟心脏室性心律失常的方法和组合物 |
-
2014
- 2014-10-17 CN CN201410550212.7A patent/CN105561298A/zh active Pending
- 2014-10-17 CN CN202010283482.1A patent/CN111407882A/zh active Pending
-
2015
- 2015-10-08 WO PCT/CN2015/091459 patent/WO2016058493A1/zh not_active Ceased
- 2015-10-08 KR KR1020237039263A patent/KR20230159650A/ko not_active Ceased
- 2015-10-08 EP EP15850529.7A patent/EP3207940B1/en active Active
- 2015-10-08 US US15/518,730 patent/US10561709B2/en active Active
- 2015-10-08 KR KR1020177010326A patent/KR102603711B1/ko active Active
- 2015-10-08 EP EP22174662.1A patent/EP4112068A1/en active Pending
- 2015-10-08 RU RU2017116973A patent/RU2017116973A/ru not_active Application Discontinuation
- 2015-10-08 CN CN201580054201.2A patent/CN108064164A/zh active Pending
- 2015-10-08 AU AU2015333335A patent/AU2015333335B2/en active Active
- 2015-10-08 CA CA2963322A patent/CA2963322A1/en not_active Abandoned
- 2015-10-08 ES ES15850529T patent/ES2924395T3/es active Active
- 2015-10-08 JP JP2017520447A patent/JP2017532343A/ja active Pending
-
2019
- 2019-12-13 US US16/714,397 patent/US20200368317A1/en not_active Abandoned
-
2020
- 2020-08-21 JP JP2020139931A patent/JP2020193217A/ja active Pending
-
2021
- 2021-10-29 AU AU2021258063A patent/AU2021258063B2/en active Active
- 2021-12-21 US US17/558,451 patent/US20220354928A1/en not_active Abandoned
-
2022
- 2022-07-06 JP JP2022108771A patent/JP2022153417A/ja active Pending
-
2024
- 2024-08-14 JP JP2024135192A patent/JP2024164068A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20170066440A (ko) | 2017-06-14 |
| US10561709B2 (en) | 2020-02-18 |
| AU2015333335A1 (en) | 2017-04-20 |
| EP3207940A4 (en) | 2018-06-06 |
| ES2924395T3 (es) | 2022-10-06 |
| EP4112068A1 (en) | 2023-01-04 |
| US20220354928A1 (en) | 2022-11-10 |
| JP2022153417A (ja) | 2022-10-12 |
| AU2021258063B2 (en) | 2025-02-27 |
| RU2017116973A3 (ru) | 2019-05-06 |
| US20200368317A1 (en) | 2020-11-26 |
| AU2015333335B2 (en) | 2021-08-05 |
| KR102603711B1 (ko) | 2023-11-20 |
| JP2020193217A (ja) | 2020-12-03 |
| AU2021258063A1 (en) | 2021-11-25 |
| US20170232068A1 (en) | 2017-08-17 |
| EP3207940B1 (en) | 2022-06-01 |
| CN108064164A (zh) | 2018-05-22 |
| JP2017532343A (ja) | 2017-11-02 |
| EP3207940A1 (en) | 2017-08-23 |
| CN105561298A (zh) | 2016-05-11 |
| KR20230159650A (ko) | 2023-11-21 |
| WO2016058493A1 (zh) | 2016-04-21 |
| CA2963322A1 (en) | 2016-04-21 |
| JP2024164068A (ja) | 2024-11-26 |
| CN111407882A (zh) | 2020-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2017116973A (ru) | Способы применения и композиции нейрегулинов для предотвращения, лечения или замедления сердечной недостаточности с сохраненной фракцией выброса | |
| JP2017532343A5 (ru) | ||
| MX393855B (es) | Terapia de combinación que comprende un inhibidor de raf y trametinib | |
| AR083878A1 (es) | Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento | |
| ES2682670T3 (es) | Lisinas de bacteriófagos de Streptococcus para la detección y tratamiento de bacterias gram positivas | |
| EP4397372A3 (en) | Methods of treating lennox-gastaut syndrome using fenfluramine | |
| MY167232A (en) | Polypeptides binding to human complement c5 | |
| WO2015187998A3 (en) | Use of inhibitor of apoptosis protein (iap) antagonists in hiv therapy | |
| RU2017113775A (ru) | Применение нейрегулина в профилактике, лечении или отсрочке развития желудочковой аритмии и его композиция | |
| WO2011112867A8 (en) | The use of fenoterol and fenoterol analogues in the treatment of glioblastomas and astrocytomas | |
| WO2017022962A8 (ko) | Ripk 억제제를 유효성분으로 포함하는 면역질환의 예방 또는 치료용 조성물 | |
| WO2016005328A3 (en) | IMMUNOGENIC PRODUCTS BASED ON MUTEIN AMYLOID ß (Aß) AMINO ACID SEQUENCES AND USES THEREOF | |
| RU2017128296A (ru) | Композиция для лечения бесплодия | |
| JP2018509388A5 (ru) | ||
| EP4349359A3 (en) | Peptide exhibiting wrinkle-improving activity and uses thereof | |
| EA201790563A1 (ru) | Применение реслизумаба для лечения эозинофильной астмы со степенью тяжести от умеренной до тяжелой | |
| CA3010788A1 (en) | Methods of administering vasopressors | |
| WO2016040169A3 (en) | Mucolytic agents for use in tretaing pulmonary sarcoidosis | |
| RU2013122987A (ru) | Способ лечения комбинированного радиационно-термического поражения | |
| MX2016011115A (es) | Terapia inmunorreguladora contra autoinmunidad en diabetes tipo 1. | |
| AR095076A1 (es) | Péptidos y composiciones para el tratamiento de daño articular | |
| RU2017126212A (ru) | Композиция | |
| WO2015168488A3 (en) | Islet amyloid polypeptides with improved solubility | |
| EA201691498A1 (ru) | Новая мишень для лечения и профилактики диабета | |
| JP2016508517A5 (ru) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HZ9A | Changing address for correspondence with an applicant | ||
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20200805 |